https://www.selleckchem.com/pr....oducts/atezolizumab.
0% (79/415) at Week ≥18, and 11.6% (48/415) at Week ≥20. The duration of effect may vary and can exceed 20 weeks or more, which was observed in at least one injection cycle in 29.4% (40/136) subjects over the course of their treatment. Data show that incobotulinumtoxinA retreatment for upper-limb spasticity may not be required at 12-week intervals and provides evidence for flexible treatment intervals beyond this time frame.Objective The video head impulse test (vHIT) is nowadays a fast and objective method to measure vestibular fu
Like
Comment
Share
